2026 H1 - tulosraportti
82 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 213 | ||
| 179 | ||
| 135 | ||
| 240 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenSo stable around 4, surely many are just waiting to buy more if it goes under 4, with USA update we can go 50% up per day
- ·3 t sitten450.000 shares of 4kr should become somewhat more than 750.000 in total turnover??
- ·7 t sittenThe valuation for shareholders of Thor remains reasonably stable. Clear that people still have faith and that a strong upward trend is expected shortly. That is really only to be expected with a share issue price of 4.8. So there you go 😉3 t sittenhttps://www.linkedin.com/posts/contributingtosavinglives-ugcPost-7528455694639906817-4UNB/?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
- ·22 t sitten · MuokattuRoche is one of the absolute largest pharmaceutical companies in the world. And has enormous amounts of money and muscle. That they have now dosed the first patient in a Phase 1 study with Pb-212 together with Orano Med is a pretty strong signal. It shows that the big players take the isotope seriously and are willing to commit money to it in the clinic. Several such programs increase the need for Pb-212 over time, and that is good for everyone supplying the sector. Indirectly very positive, for Thor medical. Advancing Targeted Alpha Therapy: First Patient Dosed in Phase 1 Trial 🎯 We are proud to announce that the first patient has been dosed in the Phase 1 clinical study evaluating our joint two-step pretargeted radioimmunotherapy (PRIT) program with Roche. Delivering potent alpha emitters with precision requires novel delivery paradigms. The approach leverages a two-step pretargeting mechanism designed to optimize therapeutic index: 1⃣Targeting: Bispecific antibodies first localize directly to the tumor. 2⃣Payload Delivery: Chelated lead-212 is subsequently administered, binding specifically to the pretargeted tumor cells while excess radioactivity clears rapidly to spare healthy tissue. About the trial and target: The target ➡️ Carcinoembryonic antigen (CEA) – a validated biomarker heavily overexpressed across colorectal, pancreatic, gastric, and non-small cell lung cancers where significant unmet need persists. Current study ➡️ Ongoing across clinical sites in the U.S., specifically enrolling patients with metastatic colorectal cancer (mCRC). Collaboration ➡️ The clinical program is sponsored and led by Roche, with Orano Med supplying and scaling the chelated lead-212 drug substance via our industrial platform. Thank you to the investigators, clinical teams, and especially the patients participating in this trial as we advance next-generation radiopharmaceuticals. https://www.linkedin.com/posts/oranomed-radiopharmaceuticals-rlt-share-7528488046665609217-HIZL/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY&utm_campaign=share_viaOrano Med has its own production facility for Pb212 - ATLab Valenciennes The disadvantage of this is that Orano Med has to develop and produce the drugs integrated with Pb212 Thor has a very flexible business model with many radiopharma customers and pharmaceutical manufacturers: Th-232 → Th-228 → customer → Pb-212 → radiopharmaceutical → patient Orano Med goes much further in its chain: Th-232 → Ra-228 → Th-228 → Ra-224 → Pb-212 → drug production → hospital The question becomes whether the industry will utilize vertically integrated production from Orano, or will independent suppliers of Th-228 – such as Thor – become the established infrastructure in the early part of the value chain?
- 1 päivä sitten · MuokattuGood news for Thor Medical 𝐅𝐢𝐫𝐬𝐭 𝐫𝐚𝐧𝐝𝐨𝐦𝐢𝐳𝐞𝐝, 𝐜𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝 𝐬𝐚𝐟𝐞𝐭𝐲 𝐝𝐚𝐭𝐚 𝐟𝐨𝐫 𝐑𝐚𝐝𝐬𝐩𝐡𝐞𝐫𝐢𝐧® 𝐚𝐫𝐞 𝐢𝐧✅ Today Oncoinvent (OSE: ONCIN) reported the interim safety readout from our randomized Phase 2 trial in advanced ovarian cancer: 🔹 No serious adverse events assessed as related to Radspherin® among 40 treated patients 🔹 No deaths and no discontinuations due to adverse events 🔹 Independent Data Monitoring Committee: continue the trial without modification These patients have just had chemotherapy and major surgery, so good tolerability really matters. The randomized data confirm what we saw in earlier trials. 📅 Next catalyst: interim efficacy readout in April 2027 For the full announcement, please see link: https://bit.ly/4znqaAg #Radspherin #ONCIN #Biotech #Radiopharmaceuticals #OvarianCancer
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
82 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenSo stable around 4, surely many are just waiting to buy more if it goes under 4, with USA update we can go 50% up per day
- ·3 t sitten450.000 shares of 4kr should become somewhat more than 750.000 in total turnover??
- ·7 t sittenThe valuation for shareholders of Thor remains reasonably stable. Clear that people still have faith and that a strong upward trend is expected shortly. That is really only to be expected with a share issue price of 4.8. So there you go 😉3 t sittenhttps://www.linkedin.com/posts/contributingtosavinglives-ugcPost-7528455694639906817-4UNB/?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
- ·22 t sitten · MuokattuRoche is one of the absolute largest pharmaceutical companies in the world. And has enormous amounts of money and muscle. That they have now dosed the first patient in a Phase 1 study with Pb-212 together with Orano Med is a pretty strong signal. It shows that the big players take the isotope seriously and are willing to commit money to it in the clinic. Several such programs increase the need for Pb-212 over time, and that is good for everyone supplying the sector. Indirectly very positive, for Thor medical. Advancing Targeted Alpha Therapy: First Patient Dosed in Phase 1 Trial 🎯 We are proud to announce that the first patient has been dosed in the Phase 1 clinical study evaluating our joint two-step pretargeted radioimmunotherapy (PRIT) program with Roche. Delivering potent alpha emitters with precision requires novel delivery paradigms. The approach leverages a two-step pretargeting mechanism designed to optimize therapeutic index: 1⃣Targeting: Bispecific antibodies first localize directly to the tumor. 2⃣Payload Delivery: Chelated lead-212 is subsequently administered, binding specifically to the pretargeted tumor cells while excess radioactivity clears rapidly to spare healthy tissue. About the trial and target: The target ➡️ Carcinoembryonic antigen (CEA) – a validated biomarker heavily overexpressed across colorectal, pancreatic, gastric, and non-small cell lung cancers where significant unmet need persists. Current study ➡️ Ongoing across clinical sites in the U.S., specifically enrolling patients with metastatic colorectal cancer (mCRC). Collaboration ➡️ The clinical program is sponsored and led by Roche, with Orano Med supplying and scaling the chelated lead-212 drug substance via our industrial platform. Thank you to the investigators, clinical teams, and especially the patients participating in this trial as we advance next-generation radiopharmaceuticals. https://www.linkedin.com/posts/oranomed-radiopharmaceuticals-rlt-share-7528488046665609217-HIZL/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY&utm_campaign=share_viaOrano Med has its own production facility for Pb212 - ATLab Valenciennes The disadvantage of this is that Orano Med has to develop and produce the drugs integrated with Pb212 Thor has a very flexible business model with many radiopharma customers and pharmaceutical manufacturers: Th-232 → Th-228 → customer → Pb-212 → radiopharmaceutical → patient Orano Med goes much further in its chain: Th-232 → Ra-228 → Th-228 → Ra-224 → Pb-212 → drug production → hospital The question becomes whether the industry will utilize vertically integrated production from Orano, or will independent suppliers of Th-228 – such as Thor – become the established infrastructure in the early part of the value chain?
- 1 päivä sitten · MuokattuGood news for Thor Medical 𝐅𝐢𝐫𝐬𝐭 𝐫𝐚𝐧𝐝𝐨𝐦𝐢𝐳𝐞𝐝, 𝐜𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝 𝐬𝐚𝐟𝐞𝐭𝐲 𝐝𝐚𝐭𝐚 𝐟𝐨𝐫 𝐑𝐚𝐝𝐬𝐩𝐡𝐞𝐫𝐢𝐧® 𝐚𝐫𝐞 𝐢𝐧✅ Today Oncoinvent (OSE: ONCIN) reported the interim safety readout from our randomized Phase 2 trial in advanced ovarian cancer: 🔹 No serious adverse events assessed as related to Radspherin® among 40 treated patients 🔹 No deaths and no discontinuations due to adverse events 🔹 Independent Data Monitoring Committee: continue the trial without modification These patients have just had chemotherapy and major surgery, so good tolerability really matters. The randomized data confirm what we saw in earlier trials. 📅 Next catalyst: interim efficacy readout in April 2027 For the full announcement, please see link: https://bit.ly/4znqaAg #Radspherin #ONCIN #Biotech #Radiopharmaceuticals #OvarianCancer
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 213 | ||
| 179 | ||
| 135 | ||
| 240 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
82 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenSo stable around 4, surely many are just waiting to buy more if it goes under 4, with USA update we can go 50% up per day
- ·3 t sitten450.000 shares of 4kr should become somewhat more than 750.000 in total turnover??
- ·7 t sittenThe valuation for shareholders of Thor remains reasonably stable. Clear that people still have faith and that a strong upward trend is expected shortly. That is really only to be expected with a share issue price of 4.8. So there you go 😉3 t sittenhttps://www.linkedin.com/posts/contributingtosavinglives-ugcPost-7528455694639906817-4UNB/?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
- ·22 t sitten · MuokattuRoche is one of the absolute largest pharmaceutical companies in the world. And has enormous amounts of money and muscle. That they have now dosed the first patient in a Phase 1 study with Pb-212 together with Orano Med is a pretty strong signal. It shows that the big players take the isotope seriously and are willing to commit money to it in the clinic. Several such programs increase the need for Pb-212 over time, and that is good for everyone supplying the sector. Indirectly very positive, for Thor medical. Advancing Targeted Alpha Therapy: First Patient Dosed in Phase 1 Trial 🎯 We are proud to announce that the first patient has been dosed in the Phase 1 clinical study evaluating our joint two-step pretargeted radioimmunotherapy (PRIT) program with Roche. Delivering potent alpha emitters with precision requires novel delivery paradigms. The approach leverages a two-step pretargeting mechanism designed to optimize therapeutic index: 1⃣Targeting: Bispecific antibodies first localize directly to the tumor. 2⃣Payload Delivery: Chelated lead-212 is subsequently administered, binding specifically to the pretargeted tumor cells while excess radioactivity clears rapidly to spare healthy tissue. About the trial and target: The target ➡️ Carcinoembryonic antigen (CEA) – a validated biomarker heavily overexpressed across colorectal, pancreatic, gastric, and non-small cell lung cancers where significant unmet need persists. Current study ➡️ Ongoing across clinical sites in the U.S., specifically enrolling patients with metastatic colorectal cancer (mCRC). Collaboration ➡️ The clinical program is sponsored and led by Roche, with Orano Med supplying and scaling the chelated lead-212 drug substance via our industrial platform. Thank you to the investigators, clinical teams, and especially the patients participating in this trial as we advance next-generation radiopharmaceuticals. https://www.linkedin.com/posts/oranomed-radiopharmaceuticals-rlt-share-7528488046665609217-HIZL/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY&utm_campaign=share_viaOrano Med has its own production facility for Pb212 - ATLab Valenciennes The disadvantage of this is that Orano Med has to develop and produce the drugs integrated with Pb212 Thor has a very flexible business model with many radiopharma customers and pharmaceutical manufacturers: Th-232 → Th-228 → customer → Pb-212 → radiopharmaceutical → patient Orano Med goes much further in its chain: Th-232 → Ra-228 → Th-228 → Ra-224 → Pb-212 → drug production → hospital The question becomes whether the industry will utilize vertically integrated production from Orano, or will independent suppliers of Th-228 – such as Thor – become the established infrastructure in the early part of the value chain?
- 1 päivä sitten · MuokattuGood news for Thor Medical 𝐅𝐢𝐫𝐬𝐭 𝐫𝐚𝐧𝐝𝐨𝐦𝐢𝐳𝐞𝐝, 𝐜𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝 𝐬𝐚𝐟𝐞𝐭𝐲 𝐝𝐚𝐭𝐚 𝐟𝐨𝐫 𝐑𝐚𝐝𝐬𝐩𝐡𝐞𝐫𝐢𝐧® 𝐚𝐫𝐞 𝐢𝐧✅ Today Oncoinvent (OSE: ONCIN) reported the interim safety readout from our randomized Phase 2 trial in advanced ovarian cancer: 🔹 No serious adverse events assessed as related to Radspherin® among 40 treated patients 🔹 No deaths and no discontinuations due to adverse events 🔹 Independent Data Monitoring Committee: continue the trial without modification These patients have just had chemotherapy and major surgery, so good tolerability really matters. The randomized data confirm what we saw in earlier trials. 📅 Next catalyst: interim efficacy readout in April 2027 For the full announcement, please see link: https://bit.ly/4znqaAg #Radspherin #ONCIN #Biotech #Radiopharmaceuticals #OvarianCancer
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 213 | ||
| 179 | ||
| 135 | ||
| 240 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






